Skip to content

Current ratio at other companies

Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
2.7×-1.8×
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
5.5×+1.4×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×
Zymeworks logo
ZymeworksZYME
10.8×+6.1×
Precigen logo
PrecigenPGEN
4.8×+1.3×
ADMA Biologics logo
ADMA BiologicsADMA
+0.4×

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.72B+59.2%
Enterprise value$1.76B+100.0%
P/S21.7×-25.0×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×

Where this comes from

Calculated from AbCellera Biologics Inc.’s reported figures.

Based on the most recent quarter.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s current ratio?
AbCellera Biologics Inc. (ABCL) reported current ratio of 14.1× in Q1 2026.
How has AbCellera Biologics Inc.'s current ratio changed year-over-year?
AbCellera Biologics Inc.'s current ratio increased by 38.5% year-over-year, from 10.1× to 14.1×.
What is the long-term trend for AbCellera Biologics Inc.'s current ratio?
Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s current ratio has grown at a 7.6% compound annual growth rate (CAGR), from 7.9× to 11.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.